sprite-preloader
Anzeige
Mehr »
Samstag, 21.07.2018 Börsentäglich über 12.000 News von 586 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

WKN: A2JCWM ISIN: US83422E1055 Ticker-Symbol: B6C 
Aktie:
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
SOLID BIOSCIENCES INC Chart 1 Jahr
1-Woche-Intraday-Chart
SOLID BIOSCIENCES INC 1-Woche-Intraday-Chart
RealtimeGeldBriefZeit
19,56
20,55
07.06.
17.04.2018 | 18:56
(7 Leser)
Schrift ändern:
(0 Bewertungen)

ACCESSWIRE·Mehr Nachrichten von ACCESSWIRE

LOS ANGELES, CA / ACCESSWIRE / April 17, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Solid Biosciences, Inc. ('Solid Biosciences' or 'the Company') (NASDAQ: SLDB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's shares between January 25, 2018 and March 14, 2018, inclusive (the 'Class Period') are encouraged to contact the firm.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company issued false and/or misleading statements and/or failed to disclose that: (1) Solid Biosciences' lead drug candidate, SGT-001, had a high likelihood of causing adverse events in patients; (2) Solid Biosciences misled investors regarding the toxicity of SGT-001; and (3) as a result, defendants' statements in the Registration Statement regarding Solid Biosciences' business, operations, and prospects were materially false and/or misleading. When the truth was revealed to the investing public, Solid Biosciences' share price fell $18.19 per share in the aggregate, causing shareholders harm.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
Sherin Mahdavian, Esq.
Schallfirm.com

SOURCE: The Schall Law Firm


© 2018 ACCESSWIRE